- Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin® in 3L R and R Follicular Lymphoma
- Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma
- Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting
- Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment
- Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors
Nordic Nanovector ASA (NANOV:OSL) closed at 2.36, 80.17% above the 52 week low of 1.31 set on Jul 06, 2022.
1.31Jul 06 202230.22Nov 16 2021
Markit short selling activity
|Market cap||274.08m NOK|
|EPS (TTM)||-4.46 |
Data delayed at least 15 minutes, as of Aug 10 2022.